SLC5A2 and diabetic kidney disease: This study compares renal outcomes and metabolic parameters in 10 patients with early diabetic nephropathy, five treated with SGLT2 inhibitors (empagliflozin or dapagliflozin) and five with semaglutide, a type of GLP-1 receptor agonist.